TMEM61 inhibitors comprise a diverse array of chemicals that target various cellular signaling pathways and processes. These inhibitors do not interact directly with TMEM61 but influence the protein's function or expression by modulating related cellular mechanisms. The primary mode of action of these inhibitors involves altering signal transduction pathways, such as the PI3K/Akt/mTOR pathway, MAPK pathway, NF-κB signaling, and stress response pathways like JNK signaling. Chemicals like Wortmannin and LY 294002, known as PI3K inhibitors, can disrupt phosphoinositide signaling, thereby affecting cellular functions that are potentially linked to TMEM61. Similarly, compounds targeting the MAPK pathway, such as U0126 and SB 203580, modify kinase activities within the cell. These modifications can have downstream effects on proteins interacting with or regulated by these kinases. Proteasome inhibitors like Bortezomib represent another category, impacting protein degradation systems in the cell. Such inhibition can lead to altered levels of various proteins, including those associated with TMEM61.
Another crucial aspect of TMEM61 inhibitors is their impact on stress response mechanisms. Agents like Thapsigargin and Tunicamycin induce ER stress, which can influence the folding and trafficking of membrane proteins, including TMEM61. Furthermore, broad-spectrum kinase inhibitors like Staurosporine have the potential to affect multiple signaling pathways, thereby exerting a more generalized influence on cellular processes related to TMEM61. In summary, TMEM61 inhibitors are a group of chemicals that indirectly modulate the function or expression of TMEM61 by targeting various cellular pathways and processes. Their effectiveness lies in their ability to interfere with critical signaling pathways and stress responses, thereby indirectly influencing the role of TMEM61 in these cellular processes.
関連項目
Items 1 to 10 of 12 total
画面:
| 製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K阻害剤で、膜タンパク質に関連する細胞シグナル伝達経路を破壊することができる。 | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
もう一つのPI3K阻害剤で、膜関連タンパク質の機能を変化させる可能性がある。 | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MAPK経路のキナーゼであるMEKを阻害し、この経路と相互作用するタンパク質に影響を及ぼす可能性がある。 | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
P38 MAPK阻害剤は、TMEM61と相互作用する可能性のあるシグナル伝達経路を修正することができる。 | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR阻害剤で、細胞増殖経路を変化させることができ、おそらくTMEM61に関連するプロセスに影響を及ぼす。 | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
プロテアソーム阻害剤は、TMEM61が関与している可能性のあるタンパク質分解経路に影響を与える可能性がある。 | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
小胞体ストレスを誘発し、膜タンパク質の機能に影響を及ぼす可能性がある。 | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
小胞体ストレスを誘導し、膜タンパク質のプロセッシングに影響を与える。 | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
幅広いキナーゼ阻害剤で、TMEM61関連のシグナル伝達に影響を及ぼす可能性がある。 | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
NF-κBを阻害し、TMEM61が関与する細胞プロセスに影響を及ぼす可能性がある。 | ||||||